OncoHost Revenue and Competitors

Binyamina,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • OncoHost's estimated annual revenue is currently $11.9M per year.(i)
  • OncoHost's estimated revenue per employee is $201,000

Employee Data

  • OncoHost has 59 Employees.(i)
  • OncoHost grew their employee count by 4% last year.

OncoHost's People

NameTitleEmail/Phone
1
VP Clinical and Regulatory affairsReveal Email/Phone
2
Head ProductReveal Email/Phone
3
Intellectual Property DirectorReveal Email/Phone
4
Bioinformatics ScientistReveal Email/Phone
5
Senior Data ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is OncoHost?

OncoHost develops personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.

keywords:N/A

N/A

Total Funding

59

Number of Employees

$11.9M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OncoHost News

2022-04-06 - OncoHost enters trial partnership to evaluate resistance to ...

OncoHost has entered a clinical trial partnership with Roswell Park Comprehensive Cancer Center in the US to evaluate immunotherapy...

2022-04-06 - OncoHost Announces Clinical Trial Collaboration with ...

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.5M73-8%N/A
#2
$55.5M306-7%N/A